Affordable way to get tested
Feel secure with your result for an affordable price
Antigen testing like never before. Finally.
Early detection. Easy operation.
Immunoflourescence method to detect SARS-CoV-2 Neutralizing Antibodies in human serum, Plasma
WHO WE ARE
LABx Corp. specializes in the design, development and distribution of affordable, accessible, and accurate IVD diagnostic solutions. LABx firmly believes that healthcare is the right of every man, regardless of his grasp, reach, and means. As such, it is committed to scouring the earth to secure tools that will level the playing field when it comes to detecting and, ultimately, combating illness.
LABx provides diagnostic services for people who need them the most, and where it matters the most: their homes and the places they personally frequent. This is in line with our mission of bringing accessible, affordable, and accurate testing to everyone.
LABx Corp. specializes in cutting-edge diagnostics with a focus on testing for the SARS-CoV-2 virus. Through our extensive array of equipment approved by regulatory boards across the globe, LABx aims to provide next-level solutions in the field of COVID-19 testing.
WHERE WE ARE GOING
LABx seeks to provide next-generation diagnostics that are
affordable, accurate, and accessible.
To achieve this, it has partnered with the top biomedical, genetic engineering, and diagnostic institutions—both commercial and research-driven ones—across the globe. Furthermore, it continues to invest and roll out new testing options that ultimately empower the patient.
LABx aims to decentralize diagnostics away from usual hubs like hospitals.
In line with this, it plans to bring point-of-care testing capabilities closer to homes and other
similarly accessible milieus.
LABx’s goal is to make healthcare a utility that is within reach of everyone.
Towards the goal of allowing families and workers to diagnose themselves at the comfort of their workplace, school, or home, LABx is set to unveil LABx Dx, which is coming very soon.
NEWS & UPDATES
Last December 30, 2020, the Swiss Society of Microbiology (SSM) tested the Fina Ag antigen test where it surpassed the passing grade with a score of 85 for sensitivity and 99 for specificity.
LABx, in partnership with the Philippine Basketball Association and the We Test As One Group, provided SARS-CoV-2 testing for the players and staff at the PBA Bubble through the use of the Sofia 2 and Fina Ag antigen tests.
In an effort to stop the proliferation of fake medical certificates for COVID-19 testing, LABx launches a secure printed Health Visa.